MeerMinder Bedrijfsinformatie

DiaSorin - The Diagnostic Specialist Skip to main content Company Company Company Management Branches Distributors Research & Development Research & Development In Vitro Diagnostics R&D In DiaSorin Products & Solutions Products & Solutions Immunodiagnostics Molecular Diagnostics Systems News Events Investors Investors A History of success Consolidated data Information for Shareholders The Board of Directors approves the results for H1'14 REVENUES: € 110.9 million in Q2’14, in line with Q2’13 revenues at CER, with molecular business contribution equal to € 0.9 million.  DiaSorin launches the test for Vitamin D 1,25 on LIAISON DiaSorin (FTSE Mid Cap:DIA) is proud to announce the launch of its novel 1,25 Dihydroxyvitamin D assay for the quantitative determination of 1,25 Dihydroxyvitamin D levels in human serum and plasma, available on the LIAISON XL analyzer for the market outside the US only.   DiaSorin scientific contribution at IFCC WorldLab 24/06/2014 Watch the video:  Testing Vitamin D beyond 25-OH Watch the video:  Use of the Aldosterone and Renin Ratio  for earlier diagnosis of Primary Aldosteronism Congresses & Events 18 Feb 10th Congress of ECCO 12 Mar CORA 2015 25 Apr ECCMID 2015 Media Media Press Video Photo Gallery Press releases Contacts Career Career DiaSorin's profile Our Vsion Our Values Human Capital Work with us Dialog New communication area. To download technical Assays information Catalog Browse our products Search the site Search form Search Download the app Browse 2013 Interactive Report The Diagnostic Specialist DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 English Italiano DiaSorin worldwide Contacts Legal